Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: pegaptanib sodium Clear all
Completed Not applicable Interventional

Intravitreous Pegaptanib Sodium Injection in Patients With Exudative Age-Related Macular Degeneration (AMD)

NCT00088192
View directory record Official record
Conditions
Macular Degeneration
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
20
States / cities
Los Angeles, California • Bridgeport, Connecticut • Hamden, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2005 · Synced Sep 3, 2026, 12:10 PM EDT
Terminated Phase 4 Interventional

A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)

NCT00312351
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 14, 2007 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 4 Interventional Results available

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

NCT01486238
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Macugen® pegaptanib sodium
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Sep 3, 2026, 12:10 PM EDT
Not listed Phase 4 Interventional

A Clinical Trial to Explore the Safety and Efficacy of Injections of Macugen When Given Every 6 Weeks in Subjects With AMD

NCT00354445
View directory record Official record
Conditions
Age-Related Macular Degeneration (AMD)
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2007 · Synced Sep 3, 2026, 12:10 PM EDT
Terminated Phase 1Phase 2 Interventional

Macugen to Prevent Worsening of Macular Edema Following Cataract Surgery in Diabetics

NCT00346983
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2008 · Synced Sep 3, 2026, 12:10 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

NCT00358423
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib Sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2008 · Synced Sep 3, 2026, 12:10 PM EDT
Terminated Phase 4 Interventional

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

NCT00134667
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Photodynamic Therapy (PDT) with Visudyne (verteporfin), Macugen (pegaptanib sodium)
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 14, 2007 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280
View directory record Official record
Conditions
Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of Care, Macugen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 2 Interventional

Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)

NCT00088283
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
pegaptanib sodium
Drug
Lead sponsor
Eyetech Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
35
States / cities
Tucson, Arizona • Los Angeles, California • Santa Ana, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2007 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion

NCT00406107
View directory record Official record
Conditions
Branch Retinal Vein Occlusion
Interventions
pegaptanib sodium (Macugen)
Drug
Lead sponsor
Palmetto Retina Center, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
3
States / cities
Los Angeles, California • Hagerstown, Maryland • West Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2014 · Synced Sep 3, 2026, 12:10 PM EDT
Terminated Not applicable Interventional

Macugen for Histoplasmosis

NCT00272766
View directory record Official record
Conditions
Ocular Histoplasmosis, Choroidal Neovascularization
Interventions
pegaptanib sodium
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2006 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

NCT00295828
View directory record Official record
Conditions
Iris Neovascularization, Diabetic Retinopathy
Interventions
Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP)
Other · Procedure
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2008 · Synced Sep 3, 2026, 12:10 PM EDT
Not listed Phase 4 Interventional

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

NCT01486771
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Macugen ® (pegaptanib sodium)
Drug
Lead sponsor
Valley Retina Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2011 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 4 Interventional Results available

Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium

NCT01573572
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema
Interventions
pegaptanib sodium injection
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
4
States / cities
Murrieta, California • Marshalltown, Iowa • West Mifflin, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Not applicable Interventional Results available

Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema

NCT00790803
View directory record Official record
Conditions
Uveitis, Cystoid Macular Edema
Interventions
Pegaptanib
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 14, 2022 · Synced Sep 3, 2026, 12:10 PM EDT
Available No phase listed Expanded access

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

NCT01487044
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Macugen (Pegaptanib Sodium)
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMD

NCT00320775
View directory record Official record
Conditions
Macular Degeneration
Interventions
VEGF Trap
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
8
States / cities
Tuscon, Arizona • Loma Linda, California • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Sep 3, 2026, 12:10 PM EDT
Withdrawn Phase 3 Interventional

A Study of the Safety, Tolerability, and Efficacy of IVT Pre-op 0.3mg Pegaptanib Sodium Versus Sham, for Management of Tractional Retinal Detachment and Vitreous Hemorrhage With Proliferative Diabetic Retinopathy

NCT01589718
View directory record Official record
Conditions
Proliferative Diabetic Retinopathy
Interventions
Macugen, Sham
Drug
Lead sponsor
Greater Houston Retina Research
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

NCT00242580
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2016 · Synced Sep 3, 2026, 12:10 PM EDT
Completed Phase 1 Interventional

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

NCT01487070
View directory record Official record
Conditions
PDR
Interventions
Macugen (Pegaptanib Sodium)
Drug
Lead sponsor
Retina Institute of Hawaii
Other
Eligibility
Up to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Dec 6, 2011 · Synced Sep 3, 2026, 12:10 PM EDT